What could the clinical evidence from the Center for Fibroid Care mean for BMJ?
The study's findings could provide new clinical evidence for BMJ readers. The investigator-sponsored study, led by Taraneh Shirazian, is evaluating the Cerene® Cryotherapy Device for women with adenomyosis. The study is designed to generate additional scientific and clinical evidence regarding the device's effectiveness in improving abnormal uterine bleeding, dysmenorrhea, and pelvic pain. If the study's results are deemed significant, they could be published in BMJ, contributing new data to the global healthcare knowledge base.
- Effect
- Mixed
- How direct
- Brind's reasoning
- When
- Within months
- The story
- No new developments lately
How it reaches BMJ
-
Channel Medsystems, Inc. announced grant support for an investigator-sponsored study at NYU Langone Health’s Center for Fibroid Care. The study is evaluating the Cerene® Cryotherapy Device in women with MRI-confirmed adenomyosis. Taraneh Shirazian, who serves as Director of the Center for Fibroid Care, is the Principal Investigator for the study.
The full event1independent outlet -
The study's primary objective is to generate additional scientific and clinical evidence regarding the treatment of adenomyosis. As a global healthcare knowledge provider, BMJ is a major venue for publishing such clinical research, potentially influencing its content and readership.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
global healthcare knowledge provider, wholly owned subsidiary of the British Medical Association
Everything about BMJ
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The study evaluates the Cerene® Cryotherapy Device in women with MRI-confirmed adenomyosis.manilatimes.net
- The study is expected to enroll up to 70 patients and follow them for 12-months post-treatment.manilatimes.net
- The study aims to evaluate the effectiveness of endometrial cryoablation in improving abnormal uterine bleeding, dysmenorrhea and pelvic pain.manilatimes.net
Why it matters
For BMJ, the publication of high-quality clinical evidence is central to its function as a global healthcare knowledge provider. The findings from this study, if published, would contribute specific, peer-reviewed data on a debilitating gynecologic condition, thereby enhancing the journal's scientific relevance in women's health.
This research addresses the need for more clinical evidence regarding treatment options for adenomyosis, a condition that causes severe issues like heavy menstrual bleeding and painful periods. The study's focus on the Cerene device provides a specific clinical angle that could inform medical practice and research globally.
What we don't know yet
- What are the clinical outcomes of the Cerene device in women with adenomyosis?
- Will the findings of the investigator-sponsored study be submitted for publication to BMJ?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- manilatimes.netWednesday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.